Lack of Coverage Decisions, Contracts Leaves Foundation Medicine With Thousands of Unpaid Tests

Nov 25, 2015

NEW YORK (GenomeWeb) – As Foundation Medicine seeks to grow revenues from its clinical cancer profiling tests, the company has been hampered by a lack of coverage decisions from Medicare and no contracts with most commercial payors, resulting in payment delays and tens of thousands of unpaid tests.

The firm provides two clinical tests for cancer patients, FoundationOne for solid tumors and FoundationOne Heme for hematologic malignancies, each assaying several hundred genes for mutations that may impact treatment decisions.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Breaking News

The Scan

The Apple's Journey

The apple has traveled westward and eastward along the Silk Road, according to a new genetic analysis.

This Week in Nature

In Nature this week: GWAS data used to reposition drugs for psychiatric use, and more.

Change Is Hard to Do

Genetic disease risk information doesn't always spur people to make healthy lifestyle changes, according to the Associated Press.

Possible Paths for CUP

A University of California, San Diego-led team has used liquid biopsies to uncover possible treatments for patients with cancers of unknown primary.

Featured White Papers

Bionano Genomics’ Next-Generation Mapping Identifies Large Structural Variants in Cancer and Genetic Disorders

Albumin & IgG Removal Reference Applications

Compatibility of POLYVIEW IHC Detection Reagents and HIGHDEF IHC Chromogens with Automated IHC Slide Stainers

Sep

20

Featured Webinar

Latest Advances in Tumor Genomic Profiling for Challenging Samples

This webinar will discuss how next-generation sequencing (NGS) can help clinical research labs and pathologists save time, money, and samples compared to single-analyte oncology research assays.

Sep

21

Featured Webinar

Processing Challenging Tumor Samples via Automated Tissue Dissection and Extraction-Free Library Prep

This webinar will demonstrate a new approach that combines precise FFPE tumor isolation with extraction-free DNA/RNA library preparation to minimize material losses and reduce the amount of tissue input required for NGS analysis.

Sep

27

Featured Webinar

Large-scale, Prospective Tumor and Normal Sequence to Accelerate Biomarker Discovery and Guide Clinical Care

This webinar will present an in-depth look at how Memorial Sloan Kettering Cancer Center has developed and implemented a next-generation sequencing panel for mutational tumor profiling of advanced cancer patients.

Main menu